Currently, Alzheimer’s Disease affects about five million people and more than 50 percent of individuals who are 85 years or older. It is the sixth leading cause of death among adults aged 65 years or older in the United States today. The disease can only be diagnosed definitively after an autopsy. Once symptoms are present, the disease has progressed beyond some treatment options.
Researchers are working to detect Alzheimer’s disease earlier. One of the ways that scientists are doing this is by using next-generation sequencing (NGS) technologies for the early onset of Alzheimer’s Disease.
What does this mean for the future of healthcare? Read on to find out more about NGS and what it means for people who are at risk, as well as their families.
Next-generation sequencing (NGS) is an increasingly popular method of genetic testing that captures the specific DNA sequence at once. Traditional methods typically focus on capturing one or two genes in a time-consuming process, which can take weeks to months depending upon the number of genes being looked at.
NGS has revolutionized how this type of testing occurs because it allows for the specific genome to be analyzed at once, which takes hours instead of weeks or months. This has huge implications when it comes to early-onset Alzheimer’s Disease because diagnosing dementia in its earliest stages is essential to providing patients with the most effective treatment options and ensuring their safety.
Alzheimer’s disease is caused by the accumulation of amyloid plaques and neurofibrillary tangles that inhibit communication within the brain. The earliest stages of Alzheimer’s Disease are characterized by a buildup of amyloid-beta proteins in certain areas of the brain, which can be detected through cerebrospinal fluid (CSF) testing.
NGS samples are collected through a simple cheek swab, which means that it can be used to track amyloid-beta proteins throughout the brain over time instead of just in specific areas at one given moment. This will allow for better tracking of Alzheimer’s Disease progression and enable us to have a more comprehensive understanding of how effective treatment options are.
Early detection and diagnosis are essential to ensuring that Alzheimer’s Disease patients receive effective treatment early on in their journey. NGS testing allows us to track amyloid-beta proteins over time, which means we can provide an accurate prognosis and develop a personalized care plan much sooner than was previously possible.
NGS testing also allows us to detect Alzheimer’s Disease in its earliest stages, which means that patients can be treated more aggressively and with greater success rates. This is good news for everyone – early detection leads to better treatment options, stronger family bonds during the journey, and improved quality of life all around.
Early detection is key when it comes to fighting neurological diseases such as Alzheimer’s since this gives doctors more time to develop better treatments so everyone can live a long and healthy life. The future looks bright with NGS, and early detection is the key to a better tomorrow.
For more information on Next-Generation Sequencing and it’s role in early detection of Alzheimer’s, contact us today.